Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.
- Published In:
- Clinical and experimental pharmacology & physiology, 51(5), e13854 (2024)
- Database ID:
- RPEP-08074
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-08074APA
Deshmukh, Nitin J; Kalshetti, M S; Patil, Mohan; Autade, Pankaj; Sangle, Ganesh V. (2024). Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.. Clinical and experimental pharmacology & physiology, 51(5), e13854. https://doi.org/10.1111/1440-1681.13854
MLA
Deshmukh, Nitin J, et al. "Exploring the modulatory effects of sotagliflozin on dyslipidemia in mice: The role of glucagon, fibroblast growth factor 21 and glucagon-like peptide 1.." Clinical and experimental pharmacology & physiology, 2024. https://doi.org/10.1111/1440-1681.13854
RethinkPeptides
RethinkPeptides Research Database. "Exploring the modulatory effects of sotagliflozin on dyslipi..." RPEP-08074. Retrieved from https://rethinkpeptides.com/research/deshmukh-2024-exploring-the-modulatory-effects
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.